Texas
Phase 2 colorectal cancer trials in Texas
29 Phase 2 colorectal cancer studies are recruiting participants at sites in 13 cities across Texas as of November 18, 2026, according to ClinicalTrials.gov.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Every Texas city with a recruiting study
Houston (20), Austin (4), Dallas (3), Fort Worth (2), Kingwood (2), Laredo (2), San Antonio (2), Tyler (2), Beaumont (1), Grapevine (1), Temple (1), Texas City (1), Webster (1).
The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.
Recently updated studies in Texas
Basic details from each study's public record (the 12 most recently updated of 29). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Verastem, Inc.
- Recruiting in
- Fort Worth · Houston
- Registry record
- NCT07659795 · updated
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- M.D. Anderson Cancer Center
- Recruiting in
- Houston
- Registry record
- NCT06959550 · updated
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Recruiting in
- Houston
- Registry record
- NCT04557449 · updated
A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- M.D. Anderson Cancer Center
- Recruiting in
- Houston
- Registry record
- NCT05411718 · updated
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Riboscience, LLC.
- Recruiting in
- Kingwood
- Registry record
- NCT06824064 · updated
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Oncolytics Biotech
- Recruiting in
- Houston
- Registry record
- NCT07446322 · updated
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Jazz Pharmaceuticals
- Recruiting in
- Dallas · Houston
- Registry record
- NCT06695845 · updated
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Bayer
- Recruiting in
- Houston
- Registry record
- NCT06760819 · updated
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- AbbVie
- Recruiting in
- Austin · Webster
- Registry record
- NCT06820463 · updated
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Criterium, Inc.
- Recruiting in
- San Antonio
- Registry record
- NCT06992258 · updated
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- AbbVie
- Recruiting in
- Austin · Fort Worth · Grapevine · and 1 more U.S. location
- Registry record
- NCT07023289 · updated
5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- The Methodist Hospital Research Institute
- Recruiting in
- Houston
- Registry record
- NCT06887218 · updated
Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Texas on ClinicalTrials.gov.
Ask about studies in Texas
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 2, as each study is coded in the registry.
Colorectal Phase 2 Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections